Abstracts tagged "Biologic agents"

Abstract Number: 1725 • 2016 ACR/ARHP Annual Meeting
Combination Therapy of Apremilast and Biologic Agent As a Safe Option of Psoriatic Arthritis and Psoriasis
Samy Metyas¹, Ramy Messiah², Tina Gettas², Lisa Asfahani³ and Anne Quismorio⁴, ¹University of Southern California, Keck School of Medicine, Assistant Clinical Professor Of Rheumatology, USC, Covina, CA, ²Research Associate, Covina Arthritis Clinic, covina, CA, ³Physcian Assistant, Covina Arthritis Clinic, Covina, CA, ⁴Rheumatology, Covina Arthritis, Covina, CA
Background/Purpose: Psoriasis is a chronic immune-medicated inflammatory condition that affects 2-3% of the population , which is characterized by rash, silver scaling of the skin…
Abstract Number: 2505 • 2016 ACR/ARHP Annual Meeting
Thresholds of Benefit-Risk Trade-Offs from the Patient Perspective for Treatment Decisions in Moderate-to-Severe Rheumatoid Arthritis
M. Elaine Husni¹, Jenny Griffith², Keith Betts³, Yan Song⁴ and Arijit Ganguli², ¹Rheumatology Dept A50, Cleveland Clinic, Cleveland, OH, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Los Angeles, CA, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Given the increasing number of available treatments for RA with varying efficacy and safety profiles, it is critical to understand the level of trade-offs…
Abstract Number: 2758 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?
J. Antonio Avina-Zubieta¹, Andrew Chow², Philip Baer³, John Kelsall⁴, Proton Rahman⁵, Jacqueline Stewart⁶, Boulos Haraoui⁷, Michel Zummer⁸, Emmanouil Rampakakis⁹, Eliofotisti Psaradellis¹⁰, Francois Nantel¹¹, Karina Maslova¹², Cathy Tkaczyk¹³, Brendan Osborne¹³ and Allen J Lehman¹², ¹Arthritis Research Canada, Richmond, BC, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Independent Rheumatology Practice, Scarborough, ON, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Montreal, Montreal, QC, Canada, ⁸Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Minimal disease activity (MDA) is now considered an objective target which is more attainable in psoriatic arthritis (PsA) compared to remission (DAS28 <2.6) which…
Abstract Number: 940 • 2016 ACR/ARHP Annual Meeting
A Trial of XmAb®5871, a Reversible Inhibitor of CD19+ Cells, in IgG4-Related Disease
John H. Stone¹, Zachary S. Wallace², Cory A. Perugino³, Ana D. Fernandes⁴, Paul A. Foster⁵ and Debra J. Zack⁵, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Rheumatology Unit, Massachusetts General Hospital, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, ⁵Xencor, Inc., San Diego, CA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition responsible for fibro-inflammatory lesions that can lead to irreversible damage. No approved therapies for IgG4-RD exist. We…
Abstract Number: 1727 • 2016 ACR/ARHP Annual Meeting
Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis
Benedicte Champs, Rheumatology, Medecine Toulouse Purpan Hospital, Lescure d'albigeois, France
Association between biologic therapies and major adverse cardiac events or cardiac heart failure in psoriatic arthritis or psoriasis: a meta-analysis. 1Champs B, 1Degboe Y, 1Ruyssen-Witrand…
Abstract Number: 2543 • 2016 ACR/ARHP Annual Meeting
Impact of Concomitant Methotrexate Administration on the Risk of Infections Among Rheumatoid Arthritis Patients Treated with Anti-TNF in Real-World
John Kelsall¹, Anna Jaroszynska², Louis Bessette³, Raman Joshi⁴, Isabelle Fortin⁵, Jacqueline Stewart⁶, Keltie Anderson⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Francois Nantel¹⁰, Karina Maslova¹¹, Brendan Osborne¹², Cathy Tkaczyk¹² and Allen J Lehman¹¹, ¹Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Private practice, Burlington, ON, Canada, ³Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁴William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ⁵Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁶Penticton Regional Hospital, Penticton, BC, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰19 Green belt Dr, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Methotrexate (MTX) is routinely used among rheumatoid arthritis (RA) patients treated with anti-TNF agents to enhance treatment efficacy and minimize the dose of biologic…
Abstract Number: 2945 • 2016 ACR/ARHP Annual Meeting
Systematic Review: “Efficacy and Safety of Biological Versus Immunosuppressive Therapy Compared to Placebo in the Treatment of Uveitis Associated with BehçEt’s Disease.”
Ana Urruticoechea-Arana¹, Tatiana Cobo-Ibáñez², Virginia Villaverde García³, Montserrat Santos-Gómez⁴, Kelly Vargas Osorio⁵, Federico Díaz-González⁶, Leslie Fariñas Padrón⁵, Vanesa Calvo-Río⁷ and Ricardo Blanco Alonso⁷, ¹Hospital Can Misses, Ibiza, Spain, ²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario de Móstoles, Móstoles, Spain, ⁴Rheumatology, Hospital Can Misses, Ibiza, Spain, ⁵Family and Community Medicine, Hospital Can Misses, Ibiza, Spain, ⁶Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose:
Abstract Number: 1315 • 2016 ACR/ARHP Annual Meeting
Methotrexate and TNF-Blockers for Post Chikungunya Chronic Arthritis : The Martinican Experience
Marie Blettery¹, Lauren Brunier-Agot², JULIA MARY³, Katlyne Polomat⁴, Florence MOINET⁴, Christophe Deligny⁵, Serge ARFI⁶, Georges JEAN BAPTISTE⁷ and Michel De Bandt⁸, ¹rheumatology, CHU Fort de France, Fort de France, Martinique, ²Internal medicine and rheumatology, Zobda Quitman Hospital, Fort de France, Martinique, ³RHEUMATOLOGY, CHU Fort de France, 97261, Martinique, ⁴Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, ⁵Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ⁶University Hospital, CHU Fort de France, Fort de France, Martinique, ⁷RHEUMATOLOGY, CHU MARTINIQUE, FWI, Fort-de-France, Martinique, ⁸Rheumatology department, CHU Fort de France, Fort de France, France
Background/Purpose: To describe treatments in patients with chronic post-chikungunya polyarthritis seen during the Caribbean outbreak (December 2013 - January 2015). Methods: Patients were examined by…
Abstract Number: 1956 • 2016 ACR/ARHP Annual Meeting
High Dose Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor Inhibitor Use Results in Less Radiographic Progression in Ankylosing Spondylitis – a Longitudinal Analysis
Lianne S. Gensler¹, John D. Reveille², MinJae Lee³, Thomas Learch⁴, Matthew Brown⁵, Mohammad H. Rahbar³, Michael Weisman⁶ and Michael Ward⁷, ¹Medicine/Rheumatology, UCSF, San Francisco, CA, ²Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ³Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ⁴Radiology, Cedars Sinai Medical Center, Los Angeles, CA, ⁵Queensland University of Technology, Brisbane, Australia, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷NIH/NIAMS, Bethesda, MD
Background/Purpose: Over the last decade, the disease modifying effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Tumor Necrosis Factor inhibitors (TNFi) have resulted in conflicting studies. …
Abstract Number: 2546 • 2016 ACR/ARHP Annual Meeting
Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer
Natalia V. Zamora¹, Harish Siddhanamatha², Andrea Barbo³, Jean Tayar⁴, Heather Lin⁵ and Maria Suarez-Almazor⁶, ¹Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴Department of Gentic Internal Medicine-AT & EC, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁶Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Biologic therapy for rheumatoid arthritis (RA) downregulates the immune response. Tumoral immunity is an important host mechanism against cancer progression, and for this reason,…
Abstract Number: 2950 • 2016 ACR/ARHP Annual Meeting
Cogan Syndrome: Treatment and Outcome from French Nationwide Retrospective Study and Literature Review of 62 Patients
CHARLOTTE DURTETTE¹, Mathieu Resche Regon², eric hachulla³, anne Graslands⁴, Thomas Papo^5,6, Jacques Pouchot⁷, jean Emmanuel kahn⁸, Thierry Zenone⁹, cedric landron¹⁰, benoit de Wazieres¹¹, Robin Dhote¹², Christophe Deligny¹³, Guillaume Gondran¹⁴, Edouard Pertuiset¹⁵, thomas quemeneur¹⁶, Bertrand Lioger¹⁷, Pascal Sève¹⁸, Christian Lavigne¹⁹, thomas le Galllou²⁰, Mohamed Hamidou²¹, claire delaunay²², Olivier Fain²³ and Arsene Mekinian²⁴, ¹SAINT ANTOINE HOSPITAL, PARIS, France, ²biostatistics Saint Louis Hospital, paris, France, ³chru lille hospital, lille, France, ⁴Service de Médecine interne, Hôpital Louis-Mourier, colombes, France, ⁵Department of Internal Medicine, AP-HP Bichat Hospital, Paris, France, ⁶Internal Medicine, Hôpital Bichat, Université Paris-Diderot, Paris, France, ⁷Paris University, Internal medicine, Paris, France, ⁸foch hospital, foch, France, ⁹Internal Medicine, Valence Hospital, Valence, France, ¹⁰service de médecine interne, CH Poitiers, CHU Poitiers, poitiers, France, ¹¹CHU de Nîmes, nimes, France, ¹²Internal Medicine, Hospital Avicenne, Bobigny, France, ¹³Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique, ¹⁴Internal Medicine Department, Limoges, France, ¹⁵CH René Dubos, Pontoise, France, ¹⁶valenciennes hospital, valenciennes, France, ¹⁷INTERNAL MEDICINE, tours, France, ¹⁸Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ¹⁹CHU Angers, department of Internal Medicine, Angers, France, ²⁰rennes CHU hospital, rennes, France, ²¹Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ²²Centre hospitalier niort, niort, France, ²³Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ²⁴DHU2iB, Internal Medicine Saint Antoine Hospital, PARIS, France
Background/Purpose: Methods: Sixty two patients were included with median age 37 [2-76] and 31/62 (50%) women. At the diagnosis, 61 (98%) had audiovestibular involvement,…
Abstract Number: 1319 • 2016 ACR/ARHP Annual Meeting
Chikungunya Fever in Patients on Biological and on Conventional Dmards Therapy – Results from the Brazilian Register Biobadabrasil
Aline Ranzolin¹, Angela Duarte², Claudia Marques³, Laurindo Rocha Jr⁴, Samia Araujo de Souza Studart⁵, José Caetano Macieira⁶, Monica Valeria Siqueira S de Vechi⁶, Lina Oliveira de Carvalho⁶, Ines Guimarães da Silveira⁷, Ieda Maria Magalhães Laurindo⁸ and BiobadaBrasil, ¹Rheumatology, Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil, ²Internal Medicine, Hospital das Clínicas - UFPE, Recife, Brazil, ³Hospital das Clínicas, Universidade Federal de Pernambuco, Recife - PE, Brazil, ⁴Rheumatology, Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil, ⁵Reumatologia, Hospital Geral de Fortaleza, Fortaleza, Brazil, ⁶Reumatologia, Hospital Federal de Sergipe, Aracaju, Brazil, ⁷Reumatologia, Pontificia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil, ⁸Internal Medicine - Rheumatology, Faculdade de Medicina da Universidade Nove de Julho, São Paulo, Brazil
Background/Purpose: Chikungunya fever (CHIKF) is a systemic arboviral disease manifesting with fever, acute arthritis and rash. The acute symptoms can last for days but…
Abstract Number: 1993 • 2016 ACR/ARHP Annual Meeting
The Risk of Stroke in Patients with Rheumatoid Arthritis and the Association with Competing Adverse Events
Yvette Meißner¹, Adrian Richter², Joern Kekow³, Hans Peter Tony⁴, Elke Wilden⁵, Angela Zink^6,7, Joachim Listing² and Anja Strangfeld⁷, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany, ⁴Rheumatology / Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ⁵Rheumatologist, Köln, Germany, ⁶Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁷Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for infections, hospitalizations and cardiovascular (CV) events. The association of serious adverse events (SAE) with…
Abstract Number: 2587 • 2016 ACR/ARHP Annual Meeting
The Serum Level of Reactive Oxygen Metabolities (ROM) at 12 Weeks during Treatment with Biologic Agents for Rheumatoid Arthritis Is a Predictor for the 52-Week Remission
Arata Nakajima¹, Keiichiro Yamamoto² and Koichi Nakagawa³, ¹Orthopaedics, Toho University Sakura Medical Center, Sakura, Japan, ²Orthopedics, Toho University Sakura Medical Center, Sakura, Japan, ³Toho University Sakura Medical Center, Sakura, Japan
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
Abstract Number: 2955 • 2016 ACR/ARHP Annual Meeting
Biologic Therapy in Severe Peripheral Ulcerative Keratitis (PUK). Multicenter Study of 27 Patients
Lucia C. Domínguez-Casas¹, Vanesa Calvo-Río¹, Olga Maiz², Ana Blanco³, Emma Beltran⁴, L. Martinez-Costa⁵, Maria Concepcion Alvarez de Buergo⁶, Esteban Rubio-Romero⁷, David Diaz-Valle⁸, R. López-González⁹, Angel M. Garcia-Aparicio¹⁰, Antonio Juan Mas¹¹, Natalia Palmou-Fontana¹, Miguel Angel Gonzalez-Gay¹ and Ricardo Blanco¹², ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Hospital Universitario Donostia, Donostia, Spain, ³Hospital Universitario Donostia, San Sebastian, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁵Hospital Dr. Peset., Valencia, Spain, ⁶Hosp. Rio Carrion, Palencia, Spain, ⁷Rheumatology Department,, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁸Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain, ⁹Rheumatology, Complejo Hospitalario de Zamora, Zamora, Spain, ¹⁰Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ¹¹Rheumatology, Hospital Son Llàtzer., Palma de Mallorca., Spain, ¹²Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Peripheral Ulcerative Keratitis (PUK) is a severe inflammation of the outer portions of the cornea that may be associated with systemic conditions. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].